Related Experiment Video

Updated: Aug 22, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.4K

Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia

Shira R Paul1, Douglas R Rosing2, Mark C Haigney3

  • 1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

British Journal of Haematology
|November 11, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
B lymphocytesBruton tyrosine kinase inhibitorCLLcardiologynon-Hodgkin lymphoma

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.6K

Related Experiment Videos

Last Updated: Aug 22, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.4K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.6K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

Articles linked to this work by shared authors, journal, and citation graph.

A randomized phase 2 placebo-controlled trial of clobetasol solution for oral chronic graft-versus-host disease therapy.

Blood advances·2026

Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Rivaroxaban with Cobicistat or Darunavir/Cobicistat in Healthy Participants.

Journal of acquired immune deficiency syndromes (1999)·2026

Clinical Considerations for the Care of the Tactical Athlete With Cardiovascular Abnormalities: A Scientific Statement From the American College of Cardiology and the American Heart Association.

Journal of the American College of Cardiology·2026

Clinical Considerations for the Care of the Tactical Athlete With Cardiovascular Abnormalities: A Scientific Statement From the American College of Cardiology and the American Heart Association.

Circulation·2026

Köhlmeier-Degos disease is an interferonopathy characterized by type I and II interferon-driven inflammatory vasculopathy.

Cell reports. Medicine·2026

Innovative Clinical Pharmacology, Modeling, and Simulation Strategies for Accelerating Rare Disease Drug Development.

Journal of clinical pharmacology·2026

Paediatric haematopoietic stem cell transplantation research priorities: Results from an international multi-stakeholder priority setting partnership.

British journal of haematology·2026

Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation.

British journal of haematology·2026

Flow cytometric assessment of T-cell receptor β-chain constant region 1/2 skewing as a surrogate marker for clonality in human T-cell leukaemia virus type-1-infected cells.

British journal of haematology·2026

The leukaemia in pregnancy study, a national multicentre retrospective study of pregnancy outcomes in women with concurrent or historic diagnoses of acute leukaemia.

British journal of haematology·2026

Phase 3, randomised, placebo-controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE.

British journal of haematology·2026

Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation.

British journal of haematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us